Grant Private Wealth Management Inc Sells 8,979 Shares of AbbVie Inc. $ABBV

Grant Private Wealth Management Inc lowered its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 75.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 2,915 shares of the company’s stock after selling 8,979 shares during the period. Grant Private Wealth Management Inc’s holdings in AbbVie were worth $675,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Marshall & Sullivan Inc. WA acquired a new position in AbbVie during the 2nd quarter worth about $25,000. Evolution Wealth Management Inc. acquired a new position in shares of AbbVie in the second quarter worth approximately $26,000. TD Capital Management LLC boosted its holdings in AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after acquiring an additional 58 shares during the last quarter. Spurstone Advisory Services LLC acquired a new stake in AbbVie during the 2nd quarter valued at approximately $28,000. Finally, Financial Gravity Companies Inc. bought a new position in AbbVie during the 2nd quarter worth approximately $36,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 0.3%

Shares of NYSE:ABBV opened at $224.32 on Thursday. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The business’s 50 day simple moving average is $226.87 and its two-hundred day simple moving average is $210.61. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. The firm has a market cap of $396.47 billion, a P/E ratio of 169.94, a PEG ratio of 1.27 and a beta of 0.36.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. AbbVie’s revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the firm posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is 496.97%.

Analysts Set New Price Targets

A number of research firms have recently commented on ABBV. Evercore ISI upped their price objective on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research note on Monday, September 22nd. Berenberg Bank raised shares of AbbVie from a “hold” rating to a “buy” rating and upped their price target for the company from $170.00 to $270.00 in a research report on Wednesday, September 17th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Cantor Fitzgerald set a $250.00 target price on AbbVie and gave the company an “overweight” rating in a research report on Thursday, October 9th. Finally, Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 13th. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.